GNPX
Genprex, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.50
+2.19%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.8x
Market Cap
$2.87M
MomentumView details →
1D Return
+2.19%
YTD Return
−91.17%
RSI (14)
25.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.8x
Market Cap
$2.87M
RSI (14)
25.8
MomentumView details →
1D Return
+2.19%
YTD Return
−91.17%
SummaryUpdated Jun 1, 2026
Genprex, Inc. (NASDAQ:GNPX) is a clinical-stage biotechnology company founded in 2009 and headquartered in Austin, Texas. The company went public in March 2018 and focuses on developing innovative gene therapies for patients suffering from cancer and diabetes. As a clinical-stage company, Genprex does not yet generate meaningful revenue from product sales but instead relies on raising capital to fund its research and development activities as it advances its therapeutic candidates through various stages of clinical trials.
Similar companies
Latest newsMore news →
Genprex entered into a development and manufacturing agreement with a leading U.S.-based CDMO to scale up manufacturing of its diabetes gene therapy program, transitioning from research-grade to clinical and commercial-ready production.18d agoGenprex announced a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-small cell lung cancer clinical trials.33d ago